Sitagliptin-Loaded Lipid Nanoparticles: Shuttles for Alzheimer’s Disease Treatment

Abstract Neuroinflammation plays a key role in the progression of various neurodegenerative diseases, including Alzheimer’s disease (AD). Sitagliptin, a widely used antidiabetic drug, has shown neuroprotective and anti-inflammatory effects, including the reduction of tumor necrosis factor-α (TNF-α) expression. This study aimed to design, develop, and evaluate lipid-based nanoparticle formulations of sitagliptin for enhanced brain delivery and treatment of neuroinflammation. Sitagliptin-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were prepared using homogenization and ultrasonication, with formulation parameters optimized through experimental design. The optimized nanoparticles were characterized for physicochemical properties, drug release behavior, cytotoxicity, and in vivo efficacy. Both formulations successfully encapsulated sitagliptin and exhibited mean particle sizes of approximately 50 nm. Drug release studies demonstrated a slower release profile for SLNs compared with NLCs. Cytotoxicity assessment using HepG2 cells indicated that both formulations were safe at low concentrations, while NLCs showed a more favorable safety profile at higher concentrations. In a mouse model of neuroinflammation, both nanoparticle systems improved behavioral outcomes and significantly reduced TNF-α expression in brain tissue, indicating enhanced brain delivery and anti-inflammatory activity. Overall, both SLNs and NLCs effectively attenuated neuroinflammation; however, NLCs demonstrated superior efficacy and safety, highlighting their potential as a promising delivery platform for sitagliptin in the treatment of AD-associated neuroinflammation.

Authors

Institutions

Publication Details

Journal
ACS Pharmacology & Translational Science
Published
2026-11-13
DOI
https://doi.org/10.1021/acsptsci.6c00499
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sitagliptin-Loaded Lipid Nanoparticles: Shuttles for Alzheimer’s Disease Treatment

Seyed Mostafa Fazel Hoseini, Seyed Mohammad Iman Moezzi, Hajar Ashrafi, Amir Azadi et al.
2 links
ACS Pharmacology & Translational Science
Nanoparticle-Based Drug Delivery
article

Sitagliptin-Loaded Lipid Nanoparticles: Shuttles for Alzheimer’s Disease Treatment

Seyed Mostafa Fazel Hoseini, Seyed Mohammad Iman Moezzi, Hajar Ashrafi, Amir Azadi, Negin Mozafari, Reza Heidari
article en

Abstract

Abstract Neuroinflammation plays a key role in the progression of various neurodegenerative diseases, including Alzheimer’s disease (AD). Sitagliptin, a widely used antidiabetic drug, has shown neuroprotective and anti-inflammatory effects, including the reduction of tumor necrosis factor-α (TNF-α) expression. This study aimed to design, develop, and evaluate lipid-based nanoparticle formulations of sitagliptin for enhanced brain delivery and treatment of neuroinflammation. Sitagliptin-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were prepared using homogenization and ultrasonication, with formulation parameters optimized through experimental design. The optimized nanoparticles were characterized for physicochemical properties, drug release behavior, cytotoxicity, and in vivo efficacy. Both formulations successfully encapsulated sitagliptin and exhibited mean particle sizes of approximately 50 nm. Drug release studies demonstrated a slower release profile for SLNs compared with NLCs. Cytotoxicity assessment using HepG2 cells indicated that both formulations were safe at low concentrations, while NLCs showed a more favorable safety profile at higher concentrations. In a mouse model of neuroinflammation, both nanoparticle systems improved behavioral outcomes and significantly reduced TNF-α expression in brain tissue, indicating enhanced brain delivery and anti-inflammatory activity. Overall, both SLNs and NLCs effectively attenuated neuroinflammation; however, NLCs demonstrated superior efficacy and safety, highlighting their potential as a promising delivery platform for sitagliptin in the treatment of AD-associated neuroinflammation.

ACS Pharmacology & Translational Science
Shiraz University of Medical Sciences (IR)
Shiraz University of Medical Sciences, National Institute for Medical Research Development
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon